The Patent Finder

Aragon Pharmaceuticals, Inc.

37 patents currently held · Updated Nov 16, 2026
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 2 name spellings.

0
Ending by 2030
Jun 2031
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 2 fees due Dec 4 to 11, 2026 · next Dec 4
  • 1 fee due Jan 14, 2027
    The maintenance fee for Estrogen receptor modulators and uses thereof (US 9,078,871) comes due Jan 14, 2027. Unpaid by Jul 14, 2027, it lapses early.
  • 1 fee due Feb 15, 2027
    The maintenance fee for Androgen Receptor Inhibitors for the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer in Subjects with Severe Hepatic Impairment (US 11,723,898) comes due Feb 15, 2027. Unpaid by Aug 16, 2027, it lapses early.
  • 2 fees due May 17 to 24, 2027 · next May 17
  • 1 fee due Jul 7, 2027
    The maintenance fee for Crystalline Forms Of An Androgen Receptor Modulator (US 10,526,310) comes due Jul 7, 2027. Unpaid by Jan 7, 2028, it lapses early.
  • 2 fees due Aug 11 to 27, 2027 · next Aug 11
  • 1 fee due Oct 23, 2027
    The maintenance fee for Anti-Androgens for the Treatment of Metastatic Castration-Sensitive Prostate Cancer (US 11,963,952) comes due Oct 23, 2027. Unpaid by Apr 24, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 2 of the patents on this record were granted since Aug 18, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 8,703,810Estrogen receptor modulators and uses thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,078,871Estrogen receptor modulators and uses thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,299,112Estrogen receptor modulators and uses thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,455,534Estrogen receptor modulators and uses thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,187,460Estrogen receptor modulators and uses thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,193,714Fluorinated estrogen receptor modulators and uses thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,399,646Estrogen receptor modulators and uses thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,499,538Estrogen receptor modulators and uses thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,481,663Crystalline Forms of an Androgen Receptor Modulator
In force
 · High confidence
In forceHigh confidence
US 9,994,545Crystalline Forms of an Androgen Receptor Modulator
In force
 · High confidence
In forceHigh confidence
10 of 37 patents shown.
Pro members see all 37.
Pro members: see all 37 patents
Also on record, not counted in the 37: 1 patent in force now held by others · 6 lapsed for an unpaid fee · 1 surrendered on reissue. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

15 abandoned · 4 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited